PYXS MICVO shows 36% confirmed response in advanced head and neck cancer
MICVO showed a 36% confirmed response rate and 94% disease control rate in heavily pretreated head and neck cancer patients. Median PFS was 6.2 months and 12-month OS probability 79%, with manageable safety.
2 months and a 12-month OS probability of 79%. The company said safety was manageable, and efficacy was consistent across key subgroups.